All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network
During the 2nd How to Diagnose & Treat CML / MPN, the MPN Hub spoke to Tiziano Barbui, Papa Giovanni XXIII Hospital, Bergamo, IT. We asked, What needs to be considered in patients with MPN with COVID-19?
What needs to be considered in patients with MPN with COVID-19?
To introduce the topic, Barbui discusses a Swedish population-based study that reported that patients with MPN and myelofibrosis were particularly vulnerable to infections. He gives a thorough discussion on the results of an international study evaluating patients with different phenotypes of MPN and COVID-19 conducted by the European LeukemiaNet (ELN). Notably, Barbui believes that patients with MPN with COVID-19 taking ruxolitinib should not discontinue treatment during the acute COVID-19 phase due to its anti-inflammatory properties. Finally, Barbui touches upon the response rate of patients with MPN to COVID-19 vaccines.
Preventing thrombosis with ruxolitinib in polycythemia vera
Polycythemia vera (PV) is an MPN that is characterized by the overproduction of erythrocytes and may also be associated with an increase in leukocytes and thrombocytes. In most patients, PV...
Myeloproliferative neoplasms, thrombosis, and COVID-19
Myeloproliferative neoplasms (MPN) are associated with a high prevalence of thrombosis at diagnosis: 28.6% in polycythemia vera (PV), 20.7% in essential thrombocytosis, and 9.5% in...
Subscribe to get the best content related to MPN delivered to your inbox